KFG
NBIX icon

Kingdom Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Kingdom Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Buy
1,222
+1,207
+8,047% +$179K 0.05% 149
2026
Q1 		$1.98K Sell
15
-956
-98% -$127K ﹤0.01% 662
2025
Q4 		$138K Buy
+971
New +$141K 0.04% 179

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kingdom Financial Group's NBIX Position: Q2 2026 in Review

Kingdom Financial Group increased its Neurocrine Biosciences (NBIX) stake by 8,047% in Q2 2026, buying an estimated $179K and bringing the position to 1,222 shares worth $206K. The position accounts for 0.05% of the portfolio, ranked #149.

Kingdom Financial Group first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Kingdom Financial Group held 1,222 shares of Neurocrine Biosciences worth $206K as of Q2 2026.
  • Kingdom Financial Group bought 1,207 Neurocrine Biosciences shares in Q2 2026, an estimated $179K.
  • Neurocrine Biosciences made up 0.05% of Kingdom Financial Group's portfolio in Q2 2026, its #149 holding.
  • Kingdom Financial Group first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Kingdom Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.